We are really pleased with the excellent results achieved in our Phase 2/3 EASED trial.

For dyskinesiaDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixArticle explores viewpoints on role of mild cognitive impairment in Parkinson's disease Treatment with ADS-5102 did not result in worsening of PD, as measured by the MDS-UPDRS combined score . Data from the Phase 2/3 study were offered today in a poster entitled ‘Protection and Efficacy of ADS-5102 in Levodopa-Induced Dyskinesia ‘ in 11:30 am ET at the World Parkinson's Congress in Montreal, Canada.. Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial Adamas Pharmaceuticals, Inc.The genetic factors that influence our very own odds of using drugs therefore also modify our likelihood of associating with friends who perform the same. However, exposure to these drug-using peers has a second, important impact on our very own liability to make use of drugs. The study discovered that heritable influences on an individual’s own regular substance use increased as they affiliated with more drug-using peers – put simply, affiliations with substance-using peers enhances the part that heritable factors play inside our own regular substance use.